Neoplasms

All Conditions

Symptoms and General Pathology

Carcinoma

Carcinoma in Situ

Hyperplasia

Neoplasms, Glandular and Epithelial

Neoplasms by Histologic Type

a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively.

HPPH

Hassan Arshad, MD

Recent literature suggests that certain patients with squamous cell cancers of the head and neck region may benefit from photodynamic therapy whether or not they may have received prior therapy, e.g. radiation therapy

We propose to initiate a Phase 1 a clinical trial using HPPH and 665 nm light in patients with cancer of the oral cavity and/or oropharynx, including lesions of moderate to severe dysplasia, squamous carcinoma in situ and T1 squamous cells carcinoma. The study will employ a fixed HPPH dose of 4 mg/m2 infused over 1 hour, and 24 hours later light doses escalating from 100 J/cm2 to 125 and 140 J/cm2, respectively. The primary goal is the determination of the maximally tolerated PDT dose. Preliminary evidence for PDT efficacy wil also be obtained.

A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx

A Phase la Trial of Photodynamic Therapy With HPPH (2-1 (Hexyloxyethyl)-2-devinylpyropheophorbide-a) for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx.

To determine the maximally tolerated dose in the oral cavity and/or oropharynx of photodynamic therapy (PDT) using HPPH (2-1 (hexyloxyethyl)-2- devinylpyropheophorbide-a) and 665 nm light.

National Cancer Institute (NCI)

Roswell Park Cancer Institute

Respiratory Tract (Lung and Bronchial) Diseases

Heart and Blood Diseases

Blood and Lymph Conditions

Immune System Diseases

Urinary Tract, Sexual Organs, and Pregnancy Conditions

Skin and Connective Tissue Diseases

Digestive System Diseases

Ear, Nose, and Throat Diseases

Gland and Hormone Related Diseases

Rare Diseases

Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Multiple Myeloma

Neoplasms, Plasma Cell

Prostatic Neoplasms

Breast Neoplasms

Esophageal Neoplasms

Carcinoma, Hepatocellular

Cholangiocarcinoma

Ascites

Vulvar Neoplasms

Carcinoma, Renal Cell

Hypersensitivity

Carcinoma, Ductal

Carcinoma, Neuroendocrine

Pleural Effusion, Malignant

Pleural Effusion

Mesothelioma

Mesothelioma, Malignant

Anus Neoplasms

Carcinoma, Small Cell

Laryngeal Diseases

Urinary Bladder Neoplasms

Small Cell Lung Carcinoma

Carcinoma, Ovarian Epithelial

Thymoma

Thymus Neoplasms

Breast Diseases

Skin Diseases

Respiratory Tract Neoplasms

Thoracic Neoplasms

Lung Diseases

Respiratory Tract Diseases

Hemostatic Disorders

Blood Coagulation Disorders

Vascular Diseases

Paraproteinemias

Blood Protein Disorders

Hematologic Diseases

Hemorrhagic Disorders

Lymphoproliferative Disorders

Immunoproliferative Disorders

Adenocarcinoma

Adenoma

Neoplasms, Mesothelial

Pleural Neoplasms

Carcinoma, Bronchogenic

Bronchial Neoplasms

Pleural Diseases

Head and Neck Neoplasms

Liver Neoplasms

Gastrointestinal Neoplasms

Digestive System Neoplasms

Gastrointestinal Diseases

Liver Diseases

Kidney Neoplasms

Urologic Neoplasms

Urogenital Neoplasms

Urogenital Diseases

Female Urogenital Diseases

Pregnancy Complications

Female Urogenital Diseases and Pregnancy Complications

Kidney Diseases

Urologic Diseases

Male Urogenital Diseases

Esophageal Diseases

Rectal Neoplasms

Colorectal Neoplasms

Intestinal Neoplasms

Intestinal Diseases

Anus Diseases

Rectal Diseases

Urinary Bladder Diseases

Genital Neoplasms, Female

Vulvar Diseases

Genital Diseases, Female

Genital Diseases

Ovarian Neoplasms

Endocrine Gland Neoplasms

Ovarian Diseases

Adnexal Diseases

Endocrine System Diseases

Gonadal Disorders

Neuroendocrine Tumors

Neuroectodermal Tumors

Neuroectodermal Tumors, Primitive

Neoplasms, Germ Cell and Embryonal

Neoplasms, Nerve Tissue

Genital Neoplasms, Male

Genital Diseases, Male

Prostatic Diseases

Lymphatic Diseases

Esophageal Cancer

Bile Duct Cancer

Diagnosis of any kind of carcinoma with a malignant fluid (pleural effusion or ascites) where drainage is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of any kind of carcinoma where a needle biopsy or tissue resection is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of relapsed multiple myeloma where bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of acute myelogenous leukemia where a blood draw or bone marrow biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of Stage IV Triple Negative Breast Cancer where a needle biopsy is clinically indicated as part of SOC, and a new course of treatment is upcoming.

Diagnosis of any cancer where a blood draw is clinically indicated as part of SOC, a new course of treatment is upcoming, and checkpoint inhibitor therapy being considered for next line of treatment.

Mark Stevens, Ph.D.

Robert Kimmerling, Ph.D.

The primary objective of this study, sponsored by Travera in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from varying cancers and biopsy formats.

Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs

The best overall response to therapy over 24 months will be captured for correlation with test outcomes.

Travera Inc

Mouth and Tooth Diseases

Stomach Neoplasms

Pancreatic Neoplasms

Uterine Cervical Neoplasms

Melanoma

Gastrointestinal Stromal Tumors

Carcinoma, Pancreatic Ductal

Nasopharyngeal Carcinoma

Nevus, Pigmented

Nevus

Nevi and Melanomas

Skin Neoplasms

Pancreatic Diseases

Nasopharyngeal Neoplasms

Pharyngeal Neoplasms

Otorhinolaryngologic Neoplasms

Nasopharyngeal Diseases

Pharyngeal Diseases

Stomatognathic Diseases

Otorhinolaryngologic Diseases

Stomach Cancer

Herbal and Botanical

All Drugs and Chemicals

Cola

Mark Stevens, Phd

Rob Kimmerling, Phd

Sarah Ginn

The primary objective of this study, sponsored by Travera Inc. in Massachusetts, is to validate whether the mass response biomarker has potential to predict response of patients to specific therapies or therapeutic combinations using isolated tumor cells from various specimen formats including malignant fluids such as pleural effusions and ascites, core needle biopsies, fine needle aspirates, or resections.

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)

Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance

xCures

Study title	NCT ID	Conditions	Interventions	Eligibility	Organization
A Trial of Photodynamic Therapy With HPPH for Treatment of Dysplasia, Carcinoma in Situ and T1 Carcinoma of the Oral Cavity and/or Oropharynx	NCT01140178	Dysplasia Carcinoma of th... Carcinoma of th...	HPPH	18 Years -	Roswell Park Cancer Institute
Defining the Clinical Potential of Mass Response as a Biomarker for Patient Tumor Sensitivity to Drugs	NCT04985357	Stage III Breas... Stage IV Breast... Stage III Lung ... Stage IV Lung C... AML Multiple Myelom... Carcinoma Carcinoma, Panc... Carcinoma of Lu... Carcinoma, Non-... Carcinoma Breas... Carcinoma Prost... Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Neur... Carcinoma, Smal... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Es... Carcinoma Cervi... Carcinoma, Thym... Carcinoma, Duct... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Malignant Pleur... Malignant Ascit... Mesothelioma Cholangiocarcin...		18 Years -	Travera Inc
Mass Response of Tumor Cells as a Biomarker for Rapid Therapy Guidance (TraveraRTGx)	NCT05461430	Pleural Effusio... Ascites, Malign... Carcinoma Carcinoma, Hepa... Carcinoma, Rena... Carcinoma, Rena... Carcinoma, Smal... Carcinoma, Non-... Carcinoma, Panc... Carcinoma, Neur... Carcinoma, Thym... Carcinoma, Panc... Carcinoma Breas... Carcinoma, Ovar... Carcinoma Bladd... Carcinoma of Un... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of Es... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Carcinoma of th... Cholangiocarcin... Melanoma Mesothelioma Pancreatic Canc...		18 Years -	Travera Inc

Spots Global Cancer Trial Database for carcinoma of the oropharynx